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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an
inherited heart muscle disease characterized by progressive fibrofatty
replacement of the right ventricular (RV) myocardium which may act
as a substrate for ventricular arrhythmias and sudden cardiac death
(SCD).1,2 The classic form of ARVC is a genetically determined car-
diomyopathy caused by heterozygous or compound mutations in
genes encoding proteins of desmosomes, which are specialized inter-
cellular structures providing mechanical attachment of myocytes.3
However, there are other genetic (non-desmosomal) and non-
genetic causes of the disease. Biventricular and left-dominant disease
variants have been identified and have led some to use the term
‘arrhythmogenic cardiomyopathy’ (ACM) to define the broader spec-
trum of the disease phenotypic expressions.2–8
However, to avoid confusion of readers, in the present
International Expert Report, the original designation of ARVC was
maintained because the document is a critical appraisal of the 2010
International Task Force (ITF) criteria that were specifically designed
to diagnose the ‘classic’ ARVC phenotype.
The current classification of ARVC includes the following clinical
variants: (i) the classic ARVC phenotype, i.e. the originally reported
and most common disease variant, characterized by isolated RV in-
volvement (Figure 1); (ii) the ‘biventricular disease variants’, i.e. ‘bal-
anced’, ‘dominant-right’ or ‘dominant-left’, characterized by the
parallel, predominant RV, and predominant left ventricular (LV) in-
volvement, respectively; and (iii) the LV phenotype characterized by
isolated LV involvement (i.e. without clinically demonstrable RV in-
volvement) (Figure 2).1–8
In 1994, an ITF proposed criteria for diagnosis of ARVC, in the
form of a qualitative scoring system which encompassed familial, elec-
trocardiographic, arrhythmic, morpho-functional, and disease fea-
tures.9 The ITF criteria were revised in 2010 by international
consensus with the intention to improve diagnostic accuracy, by pro-
viding quantitative criteria for diagnosing structural and functional RV
abnormalities, improvement of electrocardiographic criteria, and
adding molecular genetic criteria (Supplementary material online,
Table S1).10
Clinical experience with the 2010 ITF diagnostic score system has
identified limitations on the use of the criteria, potentially resulting in
disease misdiagnosis.11,12 The following problems in the use of cur-
rent ITF criteria have been identified: (i) overdiagnosis due to the in-
clusion of molecular genetic findings in the diagnostic criteria,
misinterpretation of electrocardiographic (ECG) and imaging findings,
and misdiagnosis with other diseases mimicking the ARVC pheno-
type; (ii) underdiagnosis due to absence of cardiac magnetic reson-
ance (CMR) tissue characterization findings.
In recent years, there have been evolving indications for the clinical
and imaging tests for reaching definitive diagnosis of ARVC.13–15 Due
to technological advances and increased experience in the interpret-
ation of structural, functional and tissue characterization by contrast-
enhanced CMR this has become an important imaging technique for
the diagnosis of ARVC.14 In the era of CMR, some diagnostic tests
have been abandoned because of the non-specific and limited accur-
acy, while others have been reserved for selected cases because of
the invasive nature and the risk of serious complications. Since both
the 1994 and 2010 guidelines were developed to diagnose the original
right-dominant disease phenotype they did not include specific criteria
for diagnosing LV involvement and the more recently recognized left-
sided phenotypic variants.7,8 Moreover, peculiarities of diagnosis in the
paediatric population, which represents approximately one-sixth of
the overall ARVC-population, were not addressed.16
The present international expert report is not intended to re-
design the 2010 ITF diagnostic criteria, which in the general view of
the authors are still valid and do not need substantial changes.
However, the increasing risk of misdiagnosis resulting from the in-
appropriate use of the criteria has prompted this international expert
document aimed to critically review the clinical performance and
highlight the potential limitations of current criteria, to propose some
solutions for a better clinical use and to identify potential areas of im-
provement, with particular reference to diagnosis of left-sided phe-
notypes and identification of early disease in the paediatric
population.
Overview of the 2010 diagnostic criteria
(See Supplementary material online, Text).
Current diagnostic criteria: a
critical appraisal
The following sections of the document focus on the critical evalu-
ation of each group of current diagnostic criteria and provide key sug-
gestions for improving their use in the clinical practice.
2 D. Corrado et al.
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Molecular genetics
Mutations in the genes encoding desmosomal proteins play a key
role in the pathogenesis of fibrofatty replacement of the myocardium
and the development of the disease phenotype.2,3 Pooled data from
major studies on molecular genetic screening for desmosomal gene
mutations showed that the overall rate of successful genotyping in
patients meeting the ITF diagnostic criteria is approximately 50%.17,18
The most common mutant gene is PKP2 (10–45%), followed by DSP
(10–15%), DSG2 (7–10%), and DSC2 (2%).19–21 Screening for non-
desmosomal genes marginally increases the rate of detection of gene
mutations, even though some mutations in specific genes such as
TMEM43 p.P358L22 and PLN p.R14del23 can be highly prevalent in
certain populations because of a founder effect (Supplementary ma-
terial online, Table S2). Compound/digenic heterozygosity has been
identified in up to 25% of patients and has been reported to account
for both phenotypic variability and more malignant life-time arrhyth-
mic outcome (‘dose-effect’).24–26
Different from all other forms of cardiomyopathy, the ARVC diag-
nostic criteria include the presence of a pathogenic variant in ARVC
related genes as a major criterion to establish the diagnosis.10
However, it has not been defined which mutations have sufficient evi-
dence to be considered as disease-causing and conferring pathogen-
icity to a variant can be challenging. Moreover, a negative genetic test
does not exclude the possibility that the phenotype is due to a muta-
tion in an unknown gene or that the molecular genetic screening
technique does not detect all disease-causing variants, including large
deletions or duplications.27
An increasingly emerging problem with the use of the current ITF
criteria is that the incorrect classification of a desmomosal-gene vari-
ant as ‘pathogenic’ (major criterion) or the identification of a patho-
genic variant in a gene with insufficient evidence for disease causation
may lead to a (mis)-diagnosis of ARVC in probands who otherwise
may not fulfil the ITF criteria for a (definite) phenotypic diagnosis (see
Supplementary material online, Text).
Key points
• The limitations of current understanding of the genetic basis of
ARVC and the high genetic noise due to frequent disease-
associated genetic variants both in the normal population and
other cardiomyopathies are associated with the risk of misdiag-
nosis if molecular genetic results are integral part of the diagnostic
scoring system.
• According to the general recommendations for molecular genetic
testing in inherited cardiomyopathies,28 genotyping is indicated to
identify a pathogenic or likely pathogenic mutation in a proband
who already fulfils phenotypic diagnostic criteria for ARVC, and
thus to apply mutation-specific cascade genetic testing for detec-
tion of gene carriers among family members.
• Mutation-specific genetic testing is recommended for family mem-
bers following the identification of a pathogenic or likely pathogen-
ic mutation in the proband with a clinical diagnosis of definite
ARVC, in order to identify genetically affected individuals at a pre-
clinical phase.
• Genotyping to achieve a diagnosis in a patient with borderline
phenotypic manifestations may be considered in selected cases
provided that the results are interpreted by experts on the disease
molecular genetics because the high prevalence of variants of
uncertain significance may make the genotyping results more con-
founding than confirming.
• Genetic family screening can be also indicated for arrhythmic risk
stratification purposes. In fact, compound/digenic heterozygosity of
ARVC-causing desmosomal-gene variants predicts a more serious
arrhythmic outcome because of a gene dose-effect.
• It is important to screen the entire panel of disease-related genes
including specific non-desmosomal genes, if founder mutations in
these genes are present in specific geographical areas, such as
TMEM43 in Newfoundland and PLN in the Netherlands, or when
ancestry suggests a relation with these specific geographical areas.
Myocardial tissue characterization
Invasive tissue characterization by transvenous endomyocardial bi-
opsy (EMB) has been part of the diagnostic evaluation of ARVC since
1994.9 This technique offers the potential for an in vivo histologic tis-
sue characterization with demonstration of the hallmark disease le-
sion, i.e. the loss of myocardium with fibrofatty replacement, that has
been considered the gold standard for the clinical diagnosis of ARVC
(‘major’ diagnostic criterion).29 Fatty infiltration of the RV myocar-
dium is not specific for ARVC, being reported in normal human
hearts, in the elderly and obese people.30 In this regard, the revised
ITF criteria introduced the concept that the presence of fibrosis is
also essential and provided quantitative parameters for histopatho-
logic evaluation of EMB samples, focusing on the severity of myocyte
loss and fibrosis rather than on fatty infiltration of myocardium.10 The
diagnosis of ARVC that is achieved for the first time at surgery or aut-
opsy also identifies probands and should enable cascade family
screening. The diagnostic tissue characterization can be made by
histopathology of either biopsy samples taken during cardiac surgery
performed for other reasons or in full hearts obtained at postmor-
tem or cardiac transplantation. The histologic evidence of fibrofatty
replacement of the ventricular myocardium with a subepicardial–
mid-mural distribution, or with transmural involvement in the ab-
sence of obstructive atherosclerotic plaques within the correspond-
ing coronary artery, is a diagnostic criterion for ARVC. An
immunohistochemical analysis of EMB samples for the diagnosis of
ARVC has been developed with the aim of identifying changes in the
localization of desmosomal proteins31 (see Supplementary material
online, Text).
Right ventricular endocardial voltage mapping (EVM) is an imaging
technique which may be of added value for the diagnosis of ARVC
since it has the potential to identify and quantify RV regions of elec-
troanatomic scar with low-amplitude electrical signals, typically
showing fractionation, double potentials, or conduction delay.32–34
Right ventricular EVM is an invasive, expensive and highly operator-
dependent technique with a significant risk of inaccurate interpret-
ation of low-voltage recordings in areas of normal myocardium due
to suboptimal catheter contact. Moreover, a complete EVM should
be also obtained from the epicardial side of RV, which implies a peri-
cardial puncture not justifiable solely for diagnostic purposes.
Key points
• Endomyocardial biopsy is not indicated as a routine diagnostic test
for ARVC. It should be reserved for selected patients such as pro-
bands with a sporadic form of ARVC and predominant LV involve-
ment, in whom the final diagnosis depends on histologic exclusion
Arrhythmogenic RV cardiomyopathy 3
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of phenocopies such as chronic myocarditis, sarcoidosis or other
heart muscle disorders.
• In addition to histopathologic examination of myocardial samples,
immunohistochemical analysis for evaluation of desmosomal pro-
tein localization within the intercalated disk may provide added
diagnostic value.
• Right ventricular EVM is not recommended solely for diagnostic
purposes. It should be reserved for selected ARVC patients
undergoing cardiac catheterization for arrhythmia management
and performed in electrophysiologic laboratories with a large ex-
perience in electroanatomic mapping.
• Endocardial voltage mapping-guided EMB of the RV free wall is
not performed in the majority of interventional labs and cannot be
proposed for routine diagnosis.
Global or regional dysfunction and
structural alterations
Relevant structural and functional abnormalities detectable by imag-
ing techniques include ventricular dilatation, reduced RV ejection
fraction, regional wall motion abnormalities, and fibrofatty myocardial
replacement.2,3,9,10 Contrast cine-ventriculography, echocardiog-
raphy, and CMR are the standard imaging techniques for the diagnosis
of ARVC.
Cardiac magnetic resonance has become the gold standard
method for assessing ventricular volumes, systolic function, and re-
gional wall motion, as well as to characterize myocardial tissue com-
position. Due to the spatial resolution of CMR voxels and unlimited
imaging planes that can be reconstructed, CMR offers the potential
to optimally evaluate dilatation/dysfunction, regional wall motion
abnormalities, and structural changes of the RV.13–15,35 Cine CMR
sequences provide an accurate assessment of RV volume and systolic
function. However, these parameters have low sensitivity and specifi-
city for the diagnosis of ARVC35,36 and significant interobserver vari-
ability in the interpretation of segmental contraction analysis of the
RV free wall has been reported.37–39
Tissue characterization findings by CMR (fibrosis, fatty infiltration,
and fibrofatty scar) were not included in the 2010 ITF criteria because
of limited experience, difficulty in the interpretation, and low specifi-
city.10 However, recent studies demonstrated the utility of combined
regional wall motion assessment and tissue characterization by CMR
for the diagnosis of ARVC.4 The best accuracy (98%) was present
when wall motion alterations and pre-/post-contrast signal abnormal-
ities [including LV fat infiltration and late gadolinium enhancement
(LGE)] were considered together.35
The original concept of ‘triangle of dysplasia’, which referred to the
most commonly affected regions of the RV, has evolved to the cur-
rent perspective of a ‘quadrangle of ARVC’ which also includes the
LV infero-lateral wall, which is the most frequently involved LV re-
gion. In the early stages of ARVC, the subtricuspid/peritricuspid area
and the LV infero-lateral wall may be the only affected regions.4,5,40,41
Thus, LGE imaging technique may increase diagnostic sensitivity for
ARVC, even in its early stage, by identifying a myocardial scar in the
LV infero-lateral wall, which would otherwise remain undetectable
by echocardiography/angiography because it is confined to the sub-
epicardial–mid-myocardial layers and may not be sufficiently large to
cause a systolic wall motion abnormality (Figure 2).
Inclusion of criteria for characterization of myocardial fibrofatty re-
placement offers the potential (i) to enhance the accuracy of the in-
terpretation of RV wall motion abnormalities (which has a high intra-
interobserver variability and operator dependence) by demonstrat-
ing the underlying myocardial lesion; (ii) to increase the sensitivity for
identifying forms of biventricular ARVC which are more easily diag-
nosed by CMR-imaging with demonstration of the segmental subepi-
cardial LGE in the LV wall which may be the only imaging feature of
left-dominant phenotypic variants of ARVC.
Because of its high negative predictive value, contrast-enhanced
CMR study has the potential to become the ‘rule-out’ imaging test
for evaluation of structural and functional ventricular abnormalities of
ARVC (see Supplementary material online, Text).
Key points
• Considering the technological advances and improvement of inter-
pretation of CMR tissue characterization images, acquisition and
image evaluation of biventricular myocardial fibrosis, and intramyo-
cardial fatty tissue, contrast-enhanced CMR is recommended for
definitive diagnosis and better characterization of the disease
phenotypic variant.
• Transthoracic two-dimensional echocardiography is indicated as
part of the initial evaluation of a patient with suspected ARVC.
The availability of echocardiographic findings at initial evaluation is
important in view of the subsequent serial imaging follow-up.
Echocardiographic evaluation should be repeated at 1–3 years
intervals, based on the age, genetic status, and clinical features.
• To avoid misdiagnosis, demonstration of consistent structural
and functional ventricular abnormalities is needed to reach a
definite diagnosis in a proband. Instead, overt morpho-
functional ventricular alterations may be not detectable in
affected family members, because clinical manifestations are
more subtle and may occur later over the disease course due
to the incomplete and age-dependent penetrance and the
variable phenotypic expression.
• Given the large variation of geometry and contraction of the nor-
mal RV, the presence of both regional wall motion abnormalities
and LGE should be confirmed in two orthogonal planes (e.g. hori-
zontal long-axis and short-axis views).
• Cardiac magnetic resonance should ideally be performed in high
volume centres with particular experience and expertise in imag-
ing acquisition and interpretation of ARVC features.
• Because CMR is expensive and time-consuming due to long dur-
ation of data acquisition and analysis time, follow-up with systemat-
ic serial CMR studies is unpractical. A repeat CMR study should be
considered in patients with a diagnosis of definite ARVC who de-
velop over time significant worsening of clinical symptom, ECG
abnormalities, arrhythmic events, or echocardiographic findings.
• Right ventricular angiography is not of additional diagnostic value
and should be reserved to patients in whom EMB is planned.
Cardiac catheterization is indicated when oxygen saturation meas-
urement is required for differential diagnosis between ARVC and
congenital heart diseases with a left to right shunt.
Arrhythmias
The spectrum of ventricular arrhythmias in ARVC ranges from iso-
lated premature ventricular complexes (PVCs) to sustained ventricu-
lar tachycardia (VT) or ventricular fibrillation leading to cardiac
arrest.1,4,5,18,42–44 The severity of the arrhythmia is variable between
individual patients and during the course of the disease.45,46 The
4 D. Corrado et al.
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..assessment of the morphology of the arrhythmic QRS complexes on
12-lead ECG may allow identification of the ventricular site of origin
and the mechanism of the arrhythmia.
According to the 2010 ITF diagnostic criteria, the morphology of
VT has an impact on diagnosis.10 Ventricular tachycardia with a left
bundle branch block (LBBB)/inferior axis suggesting right (or left)
ventricular outflow tract origin is considered a ‘minor’ diagnostic cri-
terion because of its low specificity which may lead to misdiagnosis of
ARVC in patients with idiopathic right ventricular outflow tract
(RVOT)-VT. However, VT with an LBBB pattern and superior or in-
determinate axis suggesting RV free wall origin is more specific for
ARVC and this is classified as a ‘major’ diagnostic criterion. VT with a
right bundle branch block (RBBB) morphology may occur as a mani-
festation of additional or predominant LV involvement.10
Studies with 24-h Holter monitoring have shown that most ARVC
patients have frequent PVCs, either isolated or coupled, with a mean
burden >500 PVC/24 h.47 Current ITF criteria consider the number
of PVCs per 24 h without addressing the morphology of the ectopic
QRS. This represents a limitation because premature ventricular
beats originating from the inferior RV wall have greater specificity for
ARVC than the number of premature ventricular beats exceeding
500/24 h or premature ventricular beats from the RVOT. It is diag-
nostically relevant to record PVCs on 12 ECG leads by exercise test-
ing or 12-lead 24-h Holter monitoring.
The electrophysiologic study has a limited role in the diagnosis of
ARVC. The test can provide information regarding the inducibility by
programmed ventricular stimulation of one or more VTs with differ-
ent rates and/or morphologies. This may be useful in differentiating
ARVC from idiopathic RVOT-VT which is a benign and non-familial
arrhythmic condition characterized by a single morphology (LBBB/in-
ferior axis) and non-inducibility by programmed ventricular stimula-
tion.48,49 Addition of RV EVM may be of incremental diagnostic value
for differential diagnosis with idiopathic RVOT-VT, provided that
care is taken to obtain adequate sampling and ensure optimal cath-
eter contact using pacing threshold assessment or direct contact
force measurements to avoid inappropriate misdiagnosis from low-
amplitude recordings. Endocardial unipolar recordings with a large
field of view may also indentify the presence of epicardial scar, thus
preventing the use of a direct pericardial approach to obtain bipolar
epicardial voltage measurements.50
Figure 1 Electrocardiographic and cardiac magnetic resonance features of a representative case of right-dominant (classic) phenotypic variant of
arrhythmogenic right ventricular cardiomyopathy. (A) Basal electrocardiographic showing T-wave inversion in right precordial leads (V1–V4). (B)
End-diastolic frame of cine cardiac magnetic resonance sequence in long-axis four-chamber view showing a dilated right ventricle (end-diastolic vol-
ume, 127 mL/m2) with a severely reduced ejection fraction (25%). The post-contrast orthogonal images in long-axis (C) and short-axis (D) views
show late gadolinium enhancement as mid-wall stria in the mid-septum (white arrow). In C, late gadolinium enhancement is also visible in the antero-
lateral, mid, and apical regions of the right ventricular wall, with segmental transmural involvement (white arrowheads) associated with regional dys-
kinesia (not shown). From De Lazzari et al.54
Arrhythmogenic RV cardiomyopathy 5
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Key points
• Twelve-lead 24-h Holter monitoring is indicated to assess the
morphology of ventricular arrhythmia, which may suggest the ven-
tricular site of origin.
• Electrophysiologic study with programmed ventricular stimulation
and RV EVM are not recommended as integral part of the routine
diagnostic evaluation of patients with ARVC. Both studies should
be limited to selected patients requiring an invasive electrophysio-
logic evaluation to distinguish ARVC-related VT from idiopathic
RVOT tachycardia.
Repolarization and depolarization
electrocardiographic abnormalities
Twelve-lead ECG is a valuable diagnostic test in ARVC and
records repolarization and/or depolarization abnormalities in up
to 90% of patients with ARVC.51–53 Negative T waves in the right
precordial leads are the most common finding (Figure 1).10 Low
QRS voltages (<0.5 mV) in the limb leads are frequently observed
in ARVC patients with fibrosis/LGE of the LV as evidenced by
CMR (Figure 2). Rather than an ECG marker of advanced RV dis-
ease, low QRS voltages indicate LV involvement (regardless of the
RV disease severity) and reflect loss of myocardium/electrical vol-
tages of the LV wall and replacement by electrically inert fibrofatty
scar tissue.54–58
The ECG abnormalities resulting from delayed RV activation/con-
duction include RBBB (usually incomplete and rarely complete), QRS
fragmentation, prolongation of right precordial QRS duration with a
delayed S-wave upstroke, terminal activation duration (TAD)
>_55 ms, and epsilon waves. The accuracy of the presence of epsilon
waves as a diagnostic tool has been questioned since these discrete
signals are related to ECG filtering and sampling rate, giving rise to
large interobserver variability.59
Figure 2 Electrocardiographic and cardiac magnetic resonance findings of a representative case of left-dominant phenotypic variant of arrhythmo-
genic right ventricular cardiomyopathy in a patient with a DSP-gene mutation and a history of sustained ventricular tachycardia. (A) Basal electrocar-
diographic showing low QRS voltages (<0.5 mV) in limb leads. (B) End-diastolic frame of cine cardiac magnetic resonance sequence in long-axis
four-chamber view showing normal cavity size and function of both ventricles. (C) Post-contrast image showing myocardial fibrosis in the form of stria
of late gadolinium enhancement in the epicardium of the left ventricular lateral wall (arrowheads) and mid-mural layer of the interventricular septum
(arrows). From De Lazzari et al.54
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Activation delay can also be detected in the form of late potentials
in the terminal portion of the QRS complex by signal-averaged ECG
(SAECG). The use of SAECG technique for diagnosis of ARVC in
probands and family members has been abandoned by most centres
because of its non-specific findings and limited diagnostic accuracy
(see Supplementary material online, Text).
Key points
• The presence of epsilon waves should be evaluated with caution,
especially in patients without other diagnostic criteria.
• A QRS delayed S-wave upstroke with TAD >_55 ms in right pre-
cordial leads is a specific diagnostic ECG pattern, particularly if fol-
lowed by negative T waves.
• Low QRS voltages (<0.5 mV) in the limb leads can be an ECG
marker predictive of LV involvement.
• Negative T waves confined to V1 and V2 should be considered as
a normal ECG variant in individuals who do not meet other diag-
nostic criteria.
Left-dominant variants of
arrhythmogenic right ventricular
cardiomyopathy
Distinctive ECG features of LV involvement in ARVC include T-wave
inversion in the infero-lateral leads and low QRS voltages (<0.5 mV)
in limb leads, which reflect the loss of myocardium and electrical vol-
tages of the LV wall.55,56 Ventricular tachycardia is characteristically
monomorphic, with a RBBB morphology which denotes its origin
form the LV.8,60 The typical LV imaging phenotype is characterized by
a ventricular remodelling pattern consisting of mild LV dysfunction
and no or mild LV dilatation, in association with a significant amount
of subepicardial/mid-myocardial (non-ischaemic) LGE affecting mul-
tiple LV segments (mostly the inferolateral wall regions) (Figure 2).61
The degree of systolic LV dysfunction appears related to the global
extent of LGE which in advanced disease affects multiple septal and
LV free wall segments.
In biventricular variants of ARVC, clinically demonstrable RV in-
volvement is an important additional criterion for differential diagno-
sis with dilated cardiomyopathy (DCM). In the absence of clinically
detectable RV involvement, demonstration of a pathogenic mutation
of ARVC-related genes, such as DSP, FLNC, and PLN genes, may sup-
port the diagnosis of ARVC (see Supplementary material online,
Text).
Key points
• Criteria for diagnosis of left-sided ARVC phenotypes should in-
clude: (i) ECG changes such as low QRS voltages in limb leads and
inverted T waves in the inferolateral leads; (ii) ventricular arrhyth-
mias with a right bundle-branch block pattern; and (iii) structural
and functional imaging features consistent with a ‘hypokinetic, non-
dilated, and fibrotic LV’.
• Clinical demonstration of some degree of electrical or structural
RV involvement should be considered as an important additional
criterion for diagnosis of biventricular or left-dominant
phenotypes.
• In patients with clinical findings suggestive of left-sided ARVC and
no clinically detectable RV involvement, genetic testing for the
presence of pathogenic mutations in ARVC-related genes, such as
the DSP gene, can confirm the diagnosis (Supplementary material
online, Table S2).
Diagnosis of arrhythmogenic right
ventricular cardiomyopathy in the
paediatric population
Arrhythmogenic RV cardiomyopathy is a genetically determined
heart muscle disease characterized by a ‘late-onset phenotype’, which
most often becomes clinically overt between the second and fourth
decades of life. Clinical manifestations of the disease are very uncom-
mon before pubertal development, whereas up to 15% of affected
patients are teenagers.62,63
Arrhythmogenic RV cardiomyopathy is a progressive heart muscle
disease with electrical and structural phenotypic manifestations
occurring at different times during its natural history. It is noteworthy
that progression of structural ventricular alterations can be preceded
and predicted by ECG depolarization abnormalities.64 Whereas adult
patients more often present with sustained VT, paediatric patients
are more likely to experience SCD or resuscitated sudden cardiac ar-
rest.45,63,65 Sudden cardiac death may be the first clinical manifest-
ation of the disease, as it was reported by a study in the Veneto
region of Italy, where 20% of SCD in young people and athletes were
caused by previously undiagnosed ARVC.66
The diagnosis of ARVC is particularly challenging in children
<14 years of age.62 Peculiarities in physiological development as well
as differences in disease presentation and progression limit the use of
the current criteria for diagnosis of ARVC in this age group.67
Diagnostic clinical work-up should be adapted to this patient popula-
tion due to the difficulty of some testing modalities in paediatric
Table 1 Differential diagnosis of arrhythmogenic right
ventricular cardiomyopathy
Mimics of right-dominant ARVC
Primary arrhythmia conditions
Right ventricular outflow tract tachycardia
Brugada syndrome
Structural diseases
Congenital heart diseases (left to right shunt, Ebstein’s anomaly,
Uhl’s anomaly)
Pulmonary artery hypertension
Athlete’s heart
Chest deformity and pericardial absence
Mimics of left-dominant ARVC
Structural diseases
Dilated cardiomyopathy
Neuromuscular cardiomyopathies (muscular dystrophies and
myofibrillar myopathies)
Myocarditis
Cardiac sarcoidosis
Congenital ventricular aneurysms
Chagas’ heart disease
Arrhythmogenic RV cardiomyopathy 7
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..patients and the low prevalence of manifest disease in very young
children. In particular, basal ECG and ambulatory ECG monitoring
can be performed at any age, while echocardiography is more easily
performed after age 3 years and cardiac CMR after age 8 years (or in
younger children but under anaesthesia) (see Supplementary material
online, Text).
Key points
• An adapted diagnostic clinical work-up using normal ECG and
imaging reference values for children should be used in the paedi-
atric population, due to the low prevalence of manifest disease,
difficulty of some testing modalities and peculiarity of clinical find-
ings in this age-group.
• Invasive studies such as RV angiography and EMB should be
reserved to very selected cases until all non-invasive studies have
been assessed.
• Molecular genetic testing for children of families affected by ARVC
is recommended for early, pre-clinical identification of genetically
affected individuals as well as for detection of non-genetically
affected siblings who can be reassured and not further investigated.
• Early detection of genetically affected children allows to establish a
focused prevention strategy mostly based on life style changes,
including restriction of competitive sports activity which is the
most important environmental factor promoting the disease
phenotypic expression.
• A follow-up by non-invasive clinical evaluation of healthy gene car-
riers or children with unknown genotype who have a positive fam-
ily history of ARVC should be performed on a regular basis after
puberty (every 1–2 years) to monitor for disease onset and
progression.
Phenocopies and differential
diagnosis
Conditions that can mimic the ARVC phenotype (phenocopies) and
enter into differential diagnosis of ARVC include primary arrhythmia
conditions and structural heart muscle diseases affecting the RV, the
LV, or both (Table 1).
Primary arrhythmia conditions
Primary arrhythmia conditions which may resemble ARVC include
idiopathic RVOT-VT and Brugada syndrome (see Supplementary ma-
terial online, Text).
Key points
• Patients with idiopathic RVOT-VT have a normal 12-lead ECG,
normal imaging tests, VT induction by isoproterenol test, and VT
non-inducible by programmed ventricular stimulation (Table 2).
• A septal origin of VT is significantly more often observed in idio-
pathic RVOT-VT than in ARVC which usually affects the RV free
wall and spares the septum.
• A single LBBB/inferior axis VT morphology favours the diagnosis
of idiopathic RVOT-VT, while multiple VT morphologies, either
spontaneous or induced, strongly suggest ARVC.68
• Brugada syndrome demonstrates substantial differences from
ARVC with respect to involved genes, absence of overt cardio-
myopathic changes, autonomic and antiarrhythmic drug modula-
tion of ECG abnormalities, circumstances and mechanisms of
arrhythmias and outcome (Table 3).
....................................................................................................................................................................................................................
Table 2 Idiopathic right ventricular outflow tract tachycardia vs arrhythmogenic right ventricular cardiomyopathy-
related ventricular tachycardia
RVOT-VT ARVC
Disease inheritance No Yes (AD)
Genetic defect No Desmosomal genes-mutations
Symptoms Palpitations, pre-syncope Palpitations, syncope, cardiac arrest
ECG abnormalities Normal Right precordial T-wave inversion, e waves, right precordial
QRS prolongation with delayed S-wave upstroke, and ter-
minal activation delay (>55 ms), low QRS voltages
Imaging Normal Structural and functional RV abnormalities
Biopsy Normal Fibrofatty myocardial replacement
Morphology of VT NSVT repetitive mono-
morphic; LBBB usually with
inferior QRS axis
LBBB Usually with left deviation
Multiple VT morphologies No Yes
VT mechanism Enhanced automaticity and
triggered activity
Scar-related re-entry
Typical site of VT origin Anteroseptal RVOT Non-septal RVOT
RV EVM Normal Low-voltage areas
Programmed ventricular stimulation Non-inducible VT Inducible VT
AD, autosomal dominant; EVM, endocardial voltage mapping; LBBB, left bundle branch block; NSVT, non-sustained ventricular tachycardia; RV, right ventricle; RVOT, right ven-
tricular outflow tract; TWI, T-wave inversion; VF, ventricular fibrillation; VT, ventricular tachycardia.
8 D. Corrado et al.
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Table 3 Brugada syndrome vs arrhythmogenic right ventricular cardiomyopathy
Brugada syndrome ARVC
Age of presentation (years) 30–40 15–30
Gender M > F (8:1) M > F (3:1)
Distribution World-wide (predominantly Southeast Asia) World-wide
Inheritance AD AD (AR)
Predominant pathogenetic genes SCN5A gene Desmosomal genes
Typical symptoms Syncope, cardiac arrest Especially nocturnal Palpitations, syncope, cardiac arrest
ECG repolarization Right precordial ST elevation and TWI Right precordial TWI
ECG depolarization RBBB/LAD Right precordial QRS prolongation, e waves
AV conduction times Prolonged PR/HV interval Normal
Variability of ECG changes Dynamic Fixed
Imaging Normal (or mild RVOT dilatation) Structural RV (and LV) abnormalities with
global and regional dilation and
dysfunction
Biopsy Normal Fibrofatty replacement
Ventricular arrhythmias Polymorphic VT, VF Monomorphic VT, VF
Mechanism of VT Phase 2 re-entry or local micro-reentry Scar-related macro-reentry
Programmed ventricular stimulation Inducibility of VF Inducibility of monomorphic VT or VF
Natural history Sudden death Sudden death, heart failure
AD, autosomal dominant; AR, autosomal recessive; AV, atrioventricular; LAD, left axis deviation; LV, left ventricle; RBBB, right bundle branch block; RV, right ventricle; RVOT,
right ventricular outflow tract; TWI, T-wave inversion; VF, ventricular fibrillation; VT, ventricular tachycardia.
Figure 3 Cardiac magnetic resonance features of heart diseases mimicking right-dominant (classic) phenotypic variant of arrhythmogenic right ven-
tricular cardiomyopathy. Partial anomalous pulmonary vein drainage (A and B): end-diastolic frame of cine cardiac magnetic resonance sequence in
long-axis four-chamber view showing moderate right ventricular dilatation (A); cine sagittal view showing the anomalous drainage of the right pul-
monary vein in the azygos vein (white arrow) (B). Ebstein anomaly (C and D): end-diastolic frame of cine cardiac magnetic resonance sequence in
short-axis view showing a severe right ventricular enlargement due to a large ventricular ‘atrialization’ (C); end-diastolic frame of cine cardiac magnetic
resonance sequence in four-chamber view showing a significant apical displacement of the septal leaflet of the tricuspid valve (white arrows) (D).
Arterial pulmonary hypertension (E and F): end-diastolic frames of cine cardiac magnetic resonance sequence in short-axis view showing increase of
the right ventricular wall thickness (white asterisk) (E), flattening of the interventricular septum (white arrows) (E), and massive pulmonary artery
dilatation (white asterisk) (F). Athlete’s heart (G and H): end-diastolic (G) and systolic (H) frames of cine cardiac magnetic resonance sequence in
four-chamber view evidencing biventricular dilatation (end-diastolic volume 122 mL/m2) and normal systolic function (ejection fraction 64%), in the
absence of wall motion abnormalities (not shown).
Arrhythmogenic RV cardiomyopathy 9
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Structural heart muscle diseases
mimicking right-dominant
arrhythmogenic right ventricular
cardiomyopathy
A number of structural conditions may mimic clinical features of
right-dominant ARVC including congenital heart diseases, pulmonary
artery hypertension, and athlete’s heart (Figure 3 and Table 4) (see
Supplementary material online, Text).
Chest deformity such as pectus excavatum or carinatum and peri-
cardial absence may cause ECG changes and echocardiographic RV
abnormalities mimicking ARVC.69
....................................................................................................................................................................................................................
Table 5 Athlete’s heart vs. arrhythmogenic right ventricular cardiomyopathy
Athlete’s heart ARVC
Family history No ARVC or SCD
ECG abnormalities Training-related ECG changes such as incom-
plete right bundle branch block increased in
QRS voltages and early repolarization. Right
precordial early repolarization variant with
negative T-wave preceded by J-point/ST-seg-
ment elevation.
Right precordial T-wave inversion, e waves, right
precordial QRS prolongation with delayed S-
wave upstroke and terminal activation delay
(>55 ms), low QRS voltages
Symptoms No Palpitations, syncope, cardiac arrest
RV dilation Yes (mainly main RV body) yes (mainly RVOT)
RV/LV dilation ratio RV/LV <1 RV/LV >1
Global RV dysfunction No (or mild) Yes
Regional RV wall motion abnormalities No A-dyskinesia; bulging
LGE at cardiac magnetic resonance No (or only junctional) RV and/or LV (non-ischaemic pattern)
Ventricular arrhythmias No Yes
LGE, late gadolinium enhancement; LV, left ventricle; RV, right ventricle; RVOT, right ventricular outflow tract; SCD, sudden cardiac death.
Table 4 Causes of right heart dilatation in adult con-
genital heart disease
Left-to-right shunt
Atrial septal defects
Partial anomalous pulmonary return
Extracardial shunts (pulmonary/systemic arteriovenous
connections)
Coronary artery fistula (to the coronary sinus/right atrium/right
ventricle)
Valvular dysfunction
Tricuspid valve regurgitation
Ebstein’s anomaly
Pulmonary valve regurgitation
Post-operative valvular insufficiency after tetralogy of Fallot repair
Myocardial malformation
Uhl’s anomaly
Ventricular aneurysm/diverticulum
Figure 4 Cardiac magnetic resonance features of dilated cardio-
myopathy vs. left-dominant phenotypic variant of arrhythmogenic
right ventricular cardiomyopathy. Dilated cardiomyopathy (A and
B): end-diastolic frame of cine cardiac magnetic resonance
sequence in four-chamber view showing severe left ventricular
dilatation (A) with severe systolic dysfunction (not shown); post-
contrast T1 inversion recovery sequence in short-axis view show-
ing limited mid-wall late gadolinium enhancement in the anterior
interventricular septum and infero-septal junction involving the ad-
jacent infero-basal wall (white arrow) (B). Left-dominant arrhyth-
mogenic right ventricular cardiomyopathy (C and D): post-contrast
T1 inversion recovery sequence in four-chamber view showing a
non-dilated (C) and hypokinetic (not shown) left ventricle; post-
contrast T1 inversion recovery sequence in short-axis view show-
ing a large amount of late gadolinium enhancement involving the
interventricular septum and both anterior and inferolateral left
ventricular walls (C and D).
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Key points
• Cardiac remodelling due to volume overload secondary to a con-
genital heart disease consists of global RV dilatation and dysfunc-
tion without regional wall motion abnormalities that allow the
differential diagnosis with the imaging findings of ARVC character-
ized by both global and regional RV dilatation and dysfunction
with prominent regional akinesia and/or dyskinesia.
• RV abnormalities of pulmonary artery hypertension are the result
of the elevation of the pulmonary artery pressure that is usually
normal or reduced in ARVC.
• The clinical phenotype of athlete’s heart differs from that of
ARVC with regard to the absence of fibrofatty myocardial replace-
ment which is clinically demonstrable as (i) regional-dyskinesia or
bulging on echo and CMR; (ii) RV LGE on CMR; (iii) ECG depolar-
ization abnormalities; and (iv) replacement type-fibrosis (and adi-
posis) at EMB70 (Table 5).
Structural heart muscle diseases
mimicking left-dominant
arrhythmogenic right ventricular
cardiomyopathy
Structural conditions mimicking clinical features of left-dominant
ARVC include DCM, cardiac involvement in genetic neuromuscular
disorders, myocarditis, sarcoidosis, congenital ventricular diverticu-
lum/aneurysm, and Chagas’ disease (see Supplementary material on-
line, Text).
Key points
• At variance with left-sided ARVC, DCM shows more severe LV
dilation and dysfunction which are unrelated to the global extent
of ventricular scar tissue as evidenced by LGE on CMR (Figure 4).
• At variance with left-sided ARVC, DCM shows scarce propensity
to life-threatening ventricular arrhythmias that occur late during
the disease course and are related to the severity of LV systolic
dysfunction (Table 6).
• Cardiomyopathy may develop in patients with various genetic
neuromuscular disorders and may occur before, during, or after
clinical evidence of skeletal muscle dysfunction. While the myocar-
dial involvement is most often part of the spectrum of pathologic
features of the disease, ventricular systolic dysfunction and/or
rhythm and conduction abnormalities may dominate the clinical
presentation or may represent the only phenotypic manifestation
of the neuromuscular gene defect (Figure 5).72
• Differential diagnosis between the cardiomyopathy occurring in
the context of a neuromuscular disease and ARVC relies on rec-
ognition of specific phenotypic features of the associated muscu-
lo–skeletal involvement.
• Identification of isolated neuromuscular cardiomyopathy (without
skeletal muscle involvement) requires demonstration of the specif-
ic genetic defect by molecular testing.
• Differential diagnosis between acute myocarditis or post-
myocarditis scar and ARVC requires accurate medical history, clin-
ical family screening, demonstration of ECG and imaging RV in-
volvement, and molecular genetic testing.
• Imaging criteria to differentiate post-myocarditis scar from inher-
ited cardiomyopathy have not been defined. Subepicardial/mid-
....................................................................................................................................................................................................................
Table 6 Dilated cardiomyopathy vs. left-dominant arrhythmogenic right ventricular cardiomyopathy
Dilated cardiomyopathy Left-dominant ARVC
Inheritance <_35% (AD) >50% (AD, AR)
Predominant genetic background Mutations of genes encoding for cytoskeleton, mus-
cular sarcomere, and nuclear envelope proteins
Mutations of genes encoding for desmosomal pro-
teins, PLN, or FLN-C
Main clinical manifestations Heart failure, cardiac arrest, palpitations Palpitations, syncope, cardiac arrest
ECG abnormalities Left ventricular hypertrophy with a strain pattern of
ST-segment; left bundle branch block
Low QRS voltages in limb leads; negative T waves
in lateral leads; negative T waves in right precor-
dial leads (biventricular form)
Echocardiography and cardiac magnetic
resonance imaging findings
Dilated and hypokinetic LV with no or patchy
non-ischaemic (mid-myocardial)
LGE (septum)
Non-dilated and hypokinetic LV with large amount
of non-ischemic (subepicardial) LGE (inferolat-
eral LV wall)
Regional wall motion abnormalities (uncommon). Regional wall motion abnormalities (common).
Systolic LV dysfunction unrelated to the global ex-
tent of LGE
Systolic LV dysfunction related to the global extent
of LGE
EMB features Non-specific myocardial abnormalities Fibrofatty myocardial replacement
Types of ventricular arrhythmias PVBs and NSVT (RBBB pattern); sustained
VT(uncommon); VF
PVBs, NSVT, and monomorphic sustained VT
(RBBB pattern; both LBBB and RBBB patterns in
biventricular form); VF
Mechanism of VT Scar-related or functional re-entry (branch to
branch re-entry)
Scar-related re-entry
Most common site of VT origin Intramural septum Subepicardial infero-lateral LV free wall
AD, autosomal dominant; AR, autosomal recessive; EMB, endomyocardial biopsy; LBBB, left bundle branch block; LV, left ventricle; NSVT, non-sustained ventricular tachycardia;
PVBs, premature ventricular beats; RBBB, right bundle branch block; RV, right ventricle; RVOT, right ventricular outflow tract; TWI, T-wave inversion; VF, ventricular fibrillation;
VT, ventricular tachycardia.
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Figure 5 Cardiac magnetic resonance features and histopathologic findings of non-ischaemic left ventricular scar of different aetiologies. Muscular
dystrophy (A and B): post-contrast T1 inversion recovery sequence in short-axis view showing a subepicardial stria of late gadolinium enhancement
in the left ventricular wall (white arrows) (A); corresponding panoramic histopathologic view of the inferolateral left ventricular wall showing replace-
ment-type fibrosis confined to the outer-mid layer of the musculature (B). Modified from Yilmaz et al.71 Chronic myocarditis (C and D): post-contrast
T1 inversion recovery sequence in short-axis view showing subepicardial late gadolinium enhancement of the inferolateral left ventricular wall (C);
corresponding panoramic histopathologic view of the inferolateral left ventricular wall showing extensive fibrous tissue replacement in the subepicar-
dial layer of the musculature (D). From Yilmaz et al.71 Desmosomal gene-related, left-sided arrhythmogenic right ventricular cardiomyopathy (E and
F): post-contrast T1 inversion recovery sequence in short-axis view showing subepicardial late gadolinium enhancement of the infero-lateral left ven-
tricular wall in a DSP-gene mutation carrier (E). Panoramic histopathologic view showing myocardial replacement of the outer layer of the infero-lat-
eral left ventricular wall in a sudden cardiac death victim carrying a DSP-gene mutation (F). From Zorzi et al.44
Figure 6 Magnetic resonance and cardiac positron emission tomography features of cardiac sarcoidosis. Post-contrast T1 inversion recovery se-
quence in four-chamber view showing right ventricular dilatation and late gadolinium enhancement of the interventricular septum (black arrows) and
subepicardial lateral left ventricular wall (white arrows) (A). Topographic concordance between the epicardial spot of late gadolinium enhancement
involving the anterior (B, single white arrow) and inferior (B, white arrows) left ventricular regions and the areas of fludeoxyglucose uptake on posi-
tron emission tomography (C, white arrows pointing to yellow–red areas).
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..myocardial LV LGE at CMR may suggest priori myocarditis but is
not diagnostic and careful family history and screening are needed
to exclude left-sided ARVC.
• The diagnosis of cardiac sarcoidosis in patients with multisystem
involvement relies on consistent clinical and imaging features of
the disease (Figure 6) in the presence of histologic evidence of
non-caseating epithelial cell granulomas in one or more organs.
• Isolated cardiac sarcoidosis is conclusively diagnosed on the basis
of EMB, possibly imaging-guided by positron emission tomography
or CMR.73,74
• The segmental nature of congenital aneurysms with associated
normal ventricular myocardium and the predominantly endocar-
dial pattern of myocardial fibrosis are not consistent with the diag-
nosis of ARVC.
• A typical history and a positive Chagas serology allow to differenti-
ate cardiac Chagas disease from ARVC.
Proposal of an aetiologic
classification of arrhythmogenic
cardiomyopathies
In about 50% of patients, ARVC is a genetic disease caused by a muta-
tion of desmosomal gene. A minority of affected patients may have
defective non-desmosomal genes. A phenotype similar to ARVC may
also occur in other genetic cardiomyopathies, cardiocutaneous syn-
dromes, or neuromuscular disorders.2,3 Furthermore, a sizeable pro-
portion of patients have non-genetic diseases with a phenotype
resembling ARVC and characterized by the distinctive propensity to
ventricular arrhythmias which extends beyond the severity of systolic
ventricular dysfunction being strongly related to the large amount of
myocardial fibrosis which is an independent arrhythmogenic risk
factor.
By analogy with current classifications of other cardiomyopathies
such as hypertrophic and dilated cardiomyopathy and in keeping with
the 2019 HRS Expert Consensus Statement on arrhythmogenic car-
diomyopathy,75 it is appropriate to propose a disease classification
which under the large umbrella of ‘arrhythmogenic cardiomyopathy’,
comprises a spectrum of conditions of different aetiologies involving
the RV, the LV or both, either genetic or non-genetic, whose com-
mon denominator is the prominent non-ischaemic ventricular myo-
cardial scarring and the scar-related ventricular arrhythmias
(Figure 7). All conditions manifesting with the ACM phenotype are
associated with a distinctively higher risk of SCD because myocardial
fibrosis acts as a substrate of malignant ventricular arrhythmias.
Accordingly, in patients affected by ACM, either genetic or non-
genetic, the implantation of an ICD for primary prevention should be
considered in the presence of large arrhythmogenic ventricular scar-
ring, even if the systolic ventricular function is not severely
depressed.76
Conclusions
A more appropriate use of the current ITF diagnostic criteria and fu-
ture upgrade/revision of the scoring system for diagnosis of ARVC
should take into account: (i) the limitation of current understanding
of the genetic background of the disease that translates into the risk
of misdiagnosis if molecular genetic test is an integral part of the diag-
nostic scoring system; (ii) the advances of technology and improve-
ment of interpretation of tissue characterization images by CMR
which has become the leading imaging technique for characterization
of the disease phenotype; (iii) the broad spectrum of the ARVC
phenotype which includes left-dominant disease variants and requires
specific diagnostic criteria from different clinical categories; and (iv)
the peculiarities of clinical features and diagnostic tests of ARVC in
the paediatric population which represents a sizeable proportion of
patients due to the increasing clinical and genetic screening of
families.
The research should focus on better understanding of the genetic
background, improvement of clinical and imaging characterization of
the phenotype, with particular reference to left-sided variants and
discovery of diagnostic biomarkers.77
Figure 7 Aetiologic classification of arrhythmogenic cardiomyopathies. The most common cause of arrhythmogenic cardiomyopathy is a genetic
defect of desmosomal genes, although there are other genetic and non-genetic causes (see the text for details).
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The clinical relevance of the proposed classification of arrhythmo-
genic cardiomyopathy remains to be evaluated by future studies.
Supplementary material
Supplementary material is available at European Heart Journal online.
Conflict of interest: none declared.
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